Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Mucinous Adenocarcinoma

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    30 result(s) found for: Mucinous Adenocarcinoma. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2010-023345-30 Sponsor Protocol Number: RAD-IPMT Start Date*: 2010-11-18
    Sponsor Name:U.L.S.S. 9 DI TREVISO
    Full Title: Prospective spontaneous cross-over study on pancreatic T1/T2 enhancement in patients with IPMT: comparison Omniscan-Dotarem
    Medical condition: Pancreatic intraductal papillary mucinous tumor
    Disease: Version SOC Term Classification Code Term Level
    9.1 10004609 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-000618-20 Sponsor Protocol Number: 40084-22084 Start Date*: 2012-11-05
    Sponsor Name:European Organization for the Research and Treatment of Cancer (EORTC)
    Full Title: A PHASE II-R and A PHASE III TRIAL EVALUATING BOTH *ERLOTINIB (PH II-R) AND CHEMORADIATION (PH III) AS ADJUVANT TREATMENT FOR PATIENTS WITH RESECTED HEAD OF PANCREAS ADENOCARCINOMA
    Medical condition: Patients with resected head of pancreas adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052747 Adenocarcinoma pancreas PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Ongoing) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-005282-39 Sponsor Protocol Number: AIRC-2013-144445 Start Date*: 2014-05-22
    Sponsor Name:Fondazione IRCCS Istituto Nazionale dei Tumori di Milano
    Full Title: Effects of high Intra-abdominal pressure on tissue diffusion and pharmacokinectics of cisplatin during HIPEC
    Medical condition: patients affected by peritoneal carcinomatosis from colorectal cancer or pseudomyxoma peritonei
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10037138 Pseudomyxoma peritonei PT
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-005725-29 Sponsor Protocol Number: EGF110656 Start Date*: 2008-05-09
    Sponsor Name:GlaxoSmithKline Research and Development
    Full Title: A Phase III Study of ErbB2 Positive Advanced or Metastatic Gastric or Esophageal Or Gastroesophageal Junction Adenocarcinoma Treated with Capecitabine Plus Oxaliplatin with or without Lapatinib
    Medical condition: Subjects with ErbB2-positive advanced or metastatic gastric or oesophageal or gastro-oesophageal junction adenocarcinoma.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001150 Adenocarcinoma gastric LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Ongoing) IT (Completed) NL (Ongoing) HU (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-003466-34 Sponsor Protocol Number: M06OVH Start Date*: 2006-12-14
    Sponsor Name:NKI-AVL
    Full Title: Phase III randomised clinical trial for stage III ovarian carcinoma randomising between secondary debulking surgery with or without hyperthermic intraperitoneal chemotherapy (OVHIPEC-I)
    Medical condition: ovarian carcinoma or peritoneal cancer (PPSC) or fallopian tube carcinoma FIGO Stage III
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-011400-33 Sponsor Protocol Number: MO22224 Start Date*: 2009-08-12
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A multi-centre, open-label, randomised, two-arm Phase III trial of bevacizumab plus chemotherapy versus chemotherapy alone in patients with platinum-resistant, epithelial ovarian, fallopian tube or...
    Medical condition: Platinum-resistant, epithelial ovarian, fallopian tube or primary peritoneal cancer
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061344 Peritoneal neoplasm PT
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016180 Fallopian tube cancer PT
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: SE (Completed) ES (Completed) PT (Completed) DE (Completed) IT (Completed) FR (Completed) DK (Completed) NL (Completed) BE (Completed) FI (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2006-006950-81 Sponsor Protocol Number: KTN32313R Start Date*: 2007-09-25
    Sponsor Name:BioNumerik Pharmaceuticals, Inc.
    Full Title: A PHASE 3 STUDY OF SAFETY AND EFFICACY OF KARENITECIN VERSUS TOPOTECAN ADMINISTERED FOR 5 CONSECUTIVE DAYS EVERY 3 WEEKS IN PATIENTS WITH ADVANCED EPITHELIAL OVARIAN CANCER
    Medical condition: advanced epithelial ovarian cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10066697 Ovarian cancer recurrent LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Prematurely Ended) HU (Prematurely Ended) LT (Prematurely Ended) PL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-005546-38 Sponsor Protocol Number: AEZS-108-050 Start Date*: 2013-10-14
    Sponsor Name:Aeterna Zentaris GmbH
    Full Title: Randomised controlled study comparing AEZS-108 with doxorubicin as second line therapy for locally advanced, recurrent or metastatic endometrial cancer
    Medical condition: Endometrial cancer, advanced, recurrent or metastatic
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014741 Endometrial cancer stage IV PT
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014740 Endometrial cancer stage III PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: CZ (Completed) BE (Completed) GB (Completed) AT (Completed) DE (Completed) ES (Completed) IE (Completed) IT (Completed) BG (Completed) NL (Completed) PL (Completed) DK (Completed) FI (Completed)
    Trial results: View results
    EudraCT Number: 2022-001843-25 Sponsor Protocol Number: BNT141-01 Start Date*: 2023-02-23
    Sponsor Name:BioNTech SE
    Full Title: Phase I/IIa, first-in-human, open-label, dose escalation trial with expansion cohorts to evaluate safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of BNT141 as a monotherapy and...
    Medical condition: CLDN18.2-positive solid tumors
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065252 Solid tumor LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017758 Gastric cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066354 Adenocarcinoma of the gastroesophageal junction LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015332 Esophageal adenocarcinoma recurrent LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033604 Pancreatic cancer LLT
    20.0 100000004871 10004676 Biliary tract disease LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008593 Cholangiocarcinoma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10063916 Metastatic gastric cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended) ES (Prematurely Ended) NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-005975-17 Sponsor Protocol Number: MO28113 Start Date*: 2012-08-17
    Sponsor Name:F. Hoffmann-La Roche Ltd.
    Full Title: A two-part, randomized Phase II, double-blind, multicenter trial assessing the efficacy and safety of pertuzumab in combination with standard chemotherapy vs. placebo plus standard chemotherapy in ...
    Medical condition: Women with recurrent platinum-resistant or refractory epithelial ovarian cancer and low HER3 mRNA expression.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed) DE (Completed) IT (Completed) NL (Completed) SE (Completed) BE (Completed) AT (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2007-003844-31 Sponsor Protocol Number: H6Q-MC-S064 Start Date*: 2007-11-28
    Sponsor Name:Eli Lilly and Company limited
    Full Title: A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Study of Enzastaurin with 5 FU/LV plus Bevacizumab as Maintenance Regimen Following First Line Therapy for Metastatic Colorectal Cancer
    Medical condition: Locally advanced or metastatic Colorectal Cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10061451 Colorectal cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) FR (Completed) IT (Prematurely Ended) AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-004372-36 Sponsor Protocol Number: BL-8040.PAC.201 Start Date*: 2019-05-21
    Sponsor Name:BioLineRx Ltd.
    Full Title: A phase IIa, multicenter, Open-Label Study to Assess the Safety and Efficacy of the Combination of BL-8040 and Pembrolizumab in Patients with Metastatic Pancreatic Cancer, the COMBAT study
    Medical condition: Pancreatic cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-000604-11 Sponsor Protocol Number: PIPAC Start Date*: 2020-07-29
    Sponsor Name:FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI"
    Full Title: Phase II study of adjuvant pressurized intraperitoneal aerosol chemotherapy (PIPAC) for the prevention of peritoneal metastases after curative-intent surgery for high-risk colorectal cancer.
    Medical condition: Patients with colon adenocarcinoma (proximal to peritoneal reflection) in stage pT4a / b, N0-2, M0, or with primitive perforated tumor undergoing curative surgery.
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055114 Colon cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-000879-26 Sponsor Protocol Number: 311602-Amendment 1 Start Date*: 2008-08-07
    Sponsor Name:Bayer Schering Pharma AG
    Full Title: (REASON) double-blind, Randomized phase II study to Evaluate the safety and efficacy of Acetyl-l-carnitine in the prevention of SagOpilone-induced peripheral Neuropathy.
    Medical condition: - Advanced refractory or relapsed ovarian cancer - Patients with metastatic hormone-refractory prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10066697 Ovarian cancer recurrent LLT
    9.1 10036909 Prostate cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) NL (Completed) BE (Completed) GB (Completed) DE (Completed) ES (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-000847-25 Sponsor Protocol Number: EMR63325-013 Start Date*: 2011-07-04
    Sponsor Name:Merck KGaA
    Full Title: A multi-center, randomized, open-label, mechanism of action trial on the biological effects of the therapeutic cancer vaccine Stimuvax® (L-BLP25) in rectal cancer subjects undergoing neoadjuvant ch...
    Medical condition: Rectal cancer subjects undergoing neoadjuvant chemoradiotherapy
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10038043 Rectal cancer Duke's C LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) PT (Completed) DE (Completed) NL (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2018-003680-62 Sponsor Protocol Number: CHIPPI-1808 Start Date*: 2019-08-06
    Sponsor Name:Centre Oscar Lambret
    Full Title: Phase III randomized clinical trial evaluating hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer considering two different settings: Primary Debulking Surgery (PDS) and Interval D...
    Medical condition: Epithelial ovarian cancer, Fallopian tube ovarian cancer, Peritoneal ovarian cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033131 Ovarian carcinoma LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016180 Fallopian tube cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052171 Peritoneal carcinoma LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-000553-23 Sponsor Protocol Number: GBG66 Start Date*: 2011-09-29
    Sponsor Name:German Breast Group GBG Forschungsgesellschaft mbH (Sponsor nach GCP)
    Full Title: A randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer
    Medical condition: patients with triple-negative breast cancer, patients with HER2-positive early breast cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10021976 Inflammatory breast cancer stage IV LLT
    14.1 100000004864 10063104 Tubular breast cancer stage II LLT
    14.1 100000004864 10065430 HER-2 positive breast cancer LLT
    14.1 100000004864 10022882 Invasive ductal breast cancer LLT
    14.1 100000004864 10028061 Mucinous breast cancer stage II LLT
    14.1 100000004864 10006188 Breast cancer female NOS LLT
    14.1 100000004864 10063105 Tubular breast cancer stage III LLT
    14.1 100000004864 10021974 Inflammatory breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-022757-42 Sponsor Protocol Number: IMM-101-002 Start Date*: 2011-05-17
    Sponsor Name:Immodulon Therapeutics Limited
    Full Title: A Randomised, Open-Label, Proof-of-Concept, Phase II Trial Comparing Gemcitabine with and without IMM-101 in Advanced Pancreatic Cancer
    Medical condition: Advanced pancreatic cancer The overall objective of this clinical study is to evaluate a potential synergy between gemcitabine and IMM-101 and any beneficial effect this may have on safety and to...
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004864 10033606 Pancreatic cancer non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) IT (Completed) IE (Completed)
    Trial results: View results
    EudraCT Number: 2012-004369-42 Sponsor Protocol Number: BAY73-4506/15983 Start Date*: 2013-11-28
    Sponsor Name:Bayer HealthCare AG
    Full Title: A Randomized, Double-blind, Placebo-controlled Phase-III Study of Adjuvant Regorafenib Versus Placebo for Patients with Stage IV Colorectal Cancer After Curative Treatment of Liver Metastases
    Medical condition: Metastatic Colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) ES (Completed) GB (Completed) IT (Completed) DE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2011-001112-53 Sponsor Protocol Number: 20101129 Start Date*: 2012-01-09
    Sponsor Name:Amgen Inc.
    Full Title: A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study of AMG 386 With Paclitaxel and Carboplatin as First-line Treatment of Subjects With FIGO Stage III-IV Epithelial Ovarian, P...
    Medical condition: FIGO Stage III-IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061269 Malignant peritoneal neoplasm PT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016180 Fallopian tube cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GR (Completed) ES (Completed) BE (Completed) NL (Completed) AT (Completed) DK (Prematurely Ended) IT (Completed) DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 01:03:57 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA